Brain Cancer
Pipeline Programs↗
Active Trials↗
Companies Involved↗
Brain Cancer is a moderately active landscape with 59 programs across 33 companies. The most active players are AstraZeneca, Nascent Biotech, Gilead. 8 therapies are approved with 8 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Analysis
Modality Breakdown
77%
Small molecule
51 of 66 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 66 classified programs, each share of the total. Modality classified for 99% of 68 pipeline programs.
Analysis
Trial Status
36
clinical trials
Clinical Trials
Trial Activity
36 trials
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)